Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Recursion Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $394.51M, down 8.5% year over year. For fiscal 2025 it was $475.27M, up 51.2% from the year before. The highest annual figure on record is $475.27M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $475.27M | +51.2% |
| FY2024 | Dec 31, 2024 | $314.42M | +30.3% |
| FY2023 | Dec 31, 2023 | $241.23M | +54.9% |
| FY2022 | Dec 31, 2022 | $155.70M | +15.1% |
| FY2021 | Dec 31, 2021 | $135.27M | +113.6% |
| FY2020 | Dec 31, 2020 | $63.32M | +38.2% |
| FY2019 | Dec 31, 2019 | $45.81M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $89.61M | -30.3% |
| Q1 FY2026 | Mar 31, 2026 | $87.90M | -32.2% |
| Q4 FY2025 | Dec 31, 2025 | $95.94M | -2.4% |
| Q3 FY2025 | Sep 30, 2025 | $121.06M | +62.3% |
| Q2 FY2025 | Jun 30, 2025 | $128.64M | +74.0% |
| Q1 FY2025 | Mar 31, 2025 | $129.63M | +91.9% |
| Q4 FY2024 | Dec 31, 2024 | $98.33M | +41.5% |
| Q3 FY2024 | Sep 30, 2024 | $74.60M | +6.6% |
| Q2 FY2024 | Jun 30, 2024 | $73.93M | +34.3% |
| Q1 FY2024 | Mar 31, 2024 | $67.56M | +44.7% |
| Q4 FY2023 | Dec 31, 2023 | $69.48M | +58.0% |
| Q3 FY2023 | Sep 30, 2023 | $70.01M | +71.4% |
| Q2 FY2023 | Jun 30, 2023 | $55.06M | +43.2% |
| Q1 FY2023 | Mar 31, 2023 | $46.68M | +43.9% |
| Q4 FY2022 | Dec 31, 2022 | $43.98M | -8.9% |
| Q3 FY2022 | Sep 30, 2022 | $40.84M | +22.8% |
| Q2 FY2022 | Jun 30, 2022 | $38.44M | +29.8% |
| Q1 FY2022 | Mar 31, 2022 | $32.44M | +34.6% |
| Q4 FY2021 | Dec 31, 2021 | $48.29M | +133.3% |
| Q3 FY2021 | Sep 30, 2021 | $33.25M | +101.1% |
| Q2 FY2021 | Jun 30, 2021 | $29.62M | +123.7% |
| Q1 FY2021 | Mar 31, 2021 | $24.11M | +87.7% |
| Q4 FY2020 | Dec 31, 2020 | $20.70M | – |
| Q3 FY2020 | Sep 30, 2020 | $16.54M | – |
| Q2 FY2020 | Jun 30, 2020 | $13.24M | – |
| Q1 FY2020 | Mar 31, 2020 | $12.84M | – |
See a number that looks wrong?